Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Amgen Inc.

A Decade of SG&A: Johnson & Johnson vs. Amgen Inc.

In the ever-evolving landscape of the pharmaceutical industry, operational efficiency is paramount. Over the past decade, Johnson & Johnson and Amgen Inc. have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Johnson & Johnson's SG&A expenses have shown a slight decline, dropping approximately 8% from 2014 to 2022, before a modest recovery in 2023. In contrast, Amgen Inc. has seen a steady increase, with a notable 31% rise over the same period. This divergence highlights differing strategic priorities: while Johnson & Johnson may be focusing on cost optimization, Amgen appears to be investing more in operational activities. These trends offer a glimpse into the strategic maneuvers of two pharmaceutical giants, each navigating the complexities of a competitive market.